Printer Friendly

IMCERA'S MALLINCKRODT MEDICAL UNIT INTRODUCES ULTRAJECT PREFILLED SYRINGE IN GERMANY

 IMCERA'S MALLINCKRODT MEDICAL UNIT INTRODUCES
 ULTRAJECT PREFILLED SYRINGE IN GERMANY
 NORTHBROOK, Ill., April 14 /PRNewswire/ -- IMCERA Group Inc. (NYSE: IMA) announced today that its Mallinckrodt Medical, Inc. German subsidiary, Mallinckrodt Medical GmbH, has introduced Ultraject(R) in Germany.
 Ultraject is a plastic syringe that is pre-filled with a single dose of contrast media for use in radiology, cardiology and urology imaging procedures. An industry first, it is designed to provide greater convenience and minimize risk of contamination or needle sticks when contrast agents are transferred from a glass bottle or vial to a syringe.
 The product was first introduced in the United States, following U.S. Food and Drug Administration (FDA) approval in 1990.
 The Ultraject delivery system will be offered with Optiray(R) (Ioversol), the company's new low-osmolar, nonionic agent which provides improved patient comfort and safety compared to traditional agents. Optiray was introduced in Germany in June 1991.
 "Ultraject represents a significant technical advance in the delivery of contrast media," said Reinhard Muller-Spath, general manager of imaging and
critical care for Mallinckrodt Medical's European operations. "The product has been well received in the U.S. since its introduction in 1990, and we are pleased to make it available to the German imaging community."
 Headquartered in St. Louis, Mallinckrodt Medical is a world leader in providing products for radiology, cardiology, nuclear medicine, anesthesiology and critical care procedures.
 IMCERA, a Fortune 250 company with net sales of more than $1.6 billion in fiscal 1991, has two other international technology-based businesses: Mallinckrodt Specialty Chemicals of Chesterfield, Mo., and Pitman-Moore of Lake Forest, Ill.
 -0- 4/14/92
 /CONTACT: Roxanna Motchan (media) of Mallinckrodt, 314-895-2078; or Dave Prichard (investors) of IMCERA, 708-205-2270/
 (IMA) CO: IMCERA Group Inc.; Mallinckrodt Medical, Inc. ST: Illinois IN: MTC SU: PDT


GK-SB -- NY059 -- 8351 04/14/92 14:25 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 14, 1992
Words:304
Previous Article:MESA AIRLINES INAUGURATES SERVICE TO LOS ANGELES
Next Article:LEP GROUP REPORTS RESULT OF EXTRAORDINARY GENERAL MEETINGS


Related Articles
IMCERA'S MALLINCKRODT MEDICAL UNIT, LIEBEL-FLARSHEIM SIGN AGREEMENT TO MAKE ULTRAJECT PREFILLED SYRINGE COMPATIBLE FOR POWER INJECTORS
IMCERA'S BOARD OF DIRECTORS APPROVES $100 MILLION PROGRAM TO EXPAND MALLINCKRODT MEDICAL'S OPTIRAY PRODUCTION CAPACITY
IMCERA'S MALLINCKRODT MEDICAL UNIT RECEIVES APPROVAL OF OPTIRAY X-RAY CONTRAST MEDIA IN JAPAN
IMCERA'S MALLINCKRODT MEDICAL UNIT TO OPERATE MO99 PRODUCTION FACILITY AT NUCLEAR MEDICINE PLANT IN THE NETHERLANDS
IMCERA'S MALLINCKRODT MEDICAL ANNOUNCES $15 MILLION EXPANSION AT RALEIGH, N.C., PLANT
MALLINCKRODT INTRODUCES OPTIRAY(R) IN ULTRAJECT(R) SYRINGES IN JAPAN, WORLD'S SECOND LARGEST MEDICAL IMAGING MARKET
Mallinckrodt Receives FDA Approval to Market Two New Pain Management Products
Mallinckrodt Introduces New OptiBolus(TM) Bolus Shaping Software For CTA Procedures.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters